PURPOSE OF REVIEW: Cancer patients may develop ocular complications secondary to direct or metastatic involvement with cancer, radiation exposure, or chemotherapy. As many as 1.4 million new cancer cases arise in the United States annually. RECENT FINDINGS: Chemotherapy administration remains a critical aspect of treating many cancers and offers improved prognosis and prolonged survival in many cases; however, these therapies are known to cause a wide range of toxicities. SUMMARY: Ocular side effects such as photophobia, cataracts, glaucoma, retinopathy, and other ocular toxicities have been reported following chemotherapy administration. To effectively treat cancer patients, oncologists, primary care clinicians, and ophthalmologists should be aware of the potential ophthalmic toxicities certain widely used chemotherapeutic agents and radiation therapy may pose to their patients, particularly in the setting of preexisting ocular conditions.
PURPOSE OF REVIEW: Cancerpatients may develop ocular complications secondary to direct or metastatic involvement with cancer, radiation exposure, or chemotherapy. As many as 1.4 million new cancer cases arise in the United States annually. RECENT FINDINGS: Chemotherapy administration remains a critical aspect of treating many cancers and offers improved prognosis and prolonged survival in many cases; however, these therapies are known to cause a wide range of toxicities. SUMMARY: Ocular side effects such as photophobia, cataracts, glaucoma, retinopathy, and other ocular toxicities have been reported following chemotherapy administration. To effectively treat cancerpatients, oncologists, primary care clinicians, and ophthalmologists should be aware of the potential ophthalmic toxicities certain widely used chemotherapeutic agents and radiation therapy may pose to their patients, particularly in the setting of preexisting ocular conditions.
Authors: A Karamitsos; V Kokkas; A Goulas; P Paraskevopoulos; K Gougoulias; V Karampatakis; K Boboridis Journal: Hippokratia Date: 2013-04 Impact factor: 0.471
Authors: D A Glaser; P Hossain; W Perkins; T Griffiths; G Ahluwalia; E Weng; F C Beddingfield Journal: Br J Dermatol Date: 2015-03-07 Impact factor: 9.302
Authors: Daniel K Roberts; Tricia L Newman; Mary Flynn Roberts; Bruce A Teitelbaum; Janis E Winters Journal: Invest Ophthalmol Vis Sci Date: 2018-04-01 Impact factor: 4.799